CD19 and lymphoma: This finding was first obtained in vitro, through the functional study of CAR.CD19-T cells cultured with lymphoma cells in the presence of high concentration of emapalumab, in standard co-culture conditions (E:T ratio of 1:1) and then confirmed with a very low E:T ratio.